J Clin Hypertens (Greenwich). 2009;11:466-474. (c)2009 Wiley Periodicals, Inc.Lower
heart failure (HF) rates in individuals taking
chlorthalidone vs
amlodipine,
lisinopril, or
doxazosin were unanticipated in the
Antihypertensive and
Lipid-Lowering Treatment to Prevent
Heart Attack Trial (ALLHAT). HF differences appeared early, leading to questions about the possible influence of pre-enrollment
antihypertensive drugs. A post hoc study evaluated hospitalized HF events. During year 1479 individuals had HF, with pre-entry
antihypertensive medication data obtained on 301 patients (63%). Case-only analysis examined interactive effects (interaction odds ratio [OR, ratio of
ORs]) of previous medication and ALLHAT treatment on HF outcomes, eg, did treatment effect differ by pre-entry
antihypertensive class? Among cases, 39%, 37%, 17%, and 47% were taking pre-entry
diuretics,
angiotensin-converting enzyme inhibitors, beta-blockers, and
calcium channel blockers, respectively. Interaction OR for year 1 HF for
amlodipine vs
chlorthalidone for patients taking vs not taking
diuretics pre-entry was 1.08 (95% confidence interval [CI], 0.53-2.21; P=.83); for
lisinopril vs
chlorthalidone, 1.33 (95% CI, 0.65-2.74; P=.44); and for
doxazosin vs
chlorthalidone, 1.13 (95% CI, 0.57-2.25; P=.73). Controlling for other pre-entry
antihypertensives yielded similar results. There was no significant evidence that pre-entry
drug type explained observed hospitalized HF differences by ALLHAT treatment.